You are here: Industry Insights > Ascentage

News List

Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses prnasia
December 15, 2021
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases...
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325 prnasia
July 29, 2021
Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, Inc., has reported encouraging ...
Ascentage Pharma's MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma, Marking the Twelfth Obtained by the Company prnasia
July 22, 2021
Ascentage announced that the US Food and Drug Administration (FDA) recently granted an Orphan Drug Designation (ODD) to the company's MDM2-p53 inhibitor, APG-115 (alrizomadlin), for the treatment of stage IIB-IV melanoma.
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax prnasia
July 20, 2021
Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company has entered into a Cooperative Research and Development Agreement ...
Innovent and Ascentage Pharma Reach Multifaceted Strategic Agreement including Joint Commercialization of Olverembatinib in China, Joint Clinical Development on Multiple Products, and Equity Investmen prnasia
July 15, 2021
Innovent Biologics, Inc and Ascentage Pharma, announced a multifaceted strategic collaboration.
Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of L prnasia
July 15, 2021
Ascentage Pharma, a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, today announced a multifaceted strategic collaboration.
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors prnasia
June 15, 2021
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the Investigational New Drug (IND) application for the ...
Ascentage Pharma to Announce Updated Data of Lisaftoclax (APG-2575) Demonstrating an ORR of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in Oral Presentation prnasia
May 20, 2021
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that an abstract reporting on the first-in-human study ...
Ascentage Selects PharmaBlock as Preferred Provider contractpharma
December 14, 2020
PharmaBlock will support Ascentage in accelerating its drug development pipeline with R&D, manufacturing capacity, and technological solutions.